Meeting
2014 ASCO Annual Meeting
Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease.
Authors
Dharminder Chauhan
Dana-Farber Cancer Institute, Boston, MA
Dharminder Chauhan , Arghya Ray , Deepika Sharma Das , Vincent Macri , Christopher Brooks , Paul G. Richardson , Eric K. Rowinsky , Kenneth Carl Anderson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8599)
DOI
10.1200/jco.2014.32.15_suppl.8599
Abstract #
8599
Poster Bd #
286
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance.
First Author: Dharminder Chauhan
Poster
2024 ASCO Annual Meeting
Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant.
First Author: Jeries Kort
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto